Your article on rational drug design (Features: research, THES , October 26) gave a good summary of current thinking about chemical modelling, given increasing costs in moving drugs through the development process. Only a small percentage of drugs make it from the laboratory bench to preclinical or phase-one trials, let alone go on to be proved efficacious and end up on the pharmacists' shelf.
Mark Lipscombe
Project manager
Origin Pharmaceutical Services Ltd
请先注册再继续
为何要注册？
- 注册是免费的，而且十分便捷
- 注册成功后，您每月可免费阅读3篇文章
- 订阅我们的邮件
已经注册或者是已订阅？
Please or to read this article.